Skip to main content

Table 1 Characterization of the study group prior IM therapy

From: Preoperative adjuvant therapy for locally advanced and recurrent/metastatic gastrointestinal stromal tumors: a retrospective study

Characteristics Patients n (%) or mean ± SD
Median age, years [range] 50.48 ± 12.51 [22–70]
GenderMale16 (64.0%)
Female9 (36.0%)
Classify of preoperative therapyIM therapy in locally advanced GISTs18 (72.0%)
IM therapy in recurrent/metastasis GISTs7 (28.0%)
Primary localizationStomach14 (56.0%)
Duodenum4 (16.0%)
Jejuno-ileum1 (4.0%)
Rectum4 (16.0%)
Pelvic/retroperitoneal2 (8.0%)
Dose of IM therapy400 mg/day22 (88.0%)
600 mg/day3 (12.0%)
Duration of preoperative therapy, months [range] 8.96 ± 4.81[3–26]
Preoperative maximal dimension, cm [range] 11.48 ± 4.46 [4.5–24.4]
Gene mutation, wild type vs. mutationKIT in exon 922 vs. 3
KIT in exon 116 vs. 19
KIT in exon 1324 vs. 1
KIT in exon 1724 vs. 1
PDGFRA in exon 1225 vs. 0
PDGFRA in exon 18(D842V)25 vs. 0
Numbers of lesionsSingle19 (76.0%)
Multiple6 (24.0%)
Response to IM therapy (according to Choi criteria)PR24 (96.0%)
SD1 (4.0%)
PD0 (0.0%)
Margin statusR024 (96.0%)
R10 (0.0%)
R21 (4.0%)
ECOG performance status018 (72.0%)
17 (28.0%)